factuality_value
stringclasses 7
values | predicat@xml:space
stringclasses 1
value | predicat@charOffset
stringlengths 3
9
| predicat@headOffset
stringlengths 3
9
| predicat@id
stringclasses 206
values | predicat@text
stringlengths 2
124
| predicat@type
stringclasses 29
values | predicat@charOffsetMin
int64 0
3.96k
| predicat@charOffsetMax
int64 6
3.97k
| subject@xml:space
stringclasses 1
value | subject@charOffset
stringlengths 3
9
| subject@headOffset
stringlengths 3
9
| subject@id
stringclasses 197
values | subject@text
stringlengths 2
49
| subject@type
stringclasses 72
values | subject@charOffsetMin
int64 0
3.98k
| subject@charOffsetMax
int64 3
4k
| object@xml:space
stringclasses 1
value | object@charOffset
stringlengths 3
9
| object@headOffset
stringlengths 3
9
| object@id
stringclasses 198
values | object@text
stringlengths 2
53
| object@type
stringclasses 73
values | object@charOffsetMin
int64 0
3.93k
| object@charOffsetMax
int64 4
3.94k
| id
stringclasses 58
values | raw_sent_text
stringlengths 20
749
| sent_charOffset
stringlengths 4
9
| sent_charOffsetMin
int64 0
3.88k
| sent_charOffsetMax
int64 26
4.2k
| formated_sentence
stringlengths 34
768
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Uncommitted | preserve | 1360-1363 | 1360-1363 | T72 | for | TREATS | 1,360 | 1,363 | preserve | 1208-1254 | 1244-1254 | T66 | angiotensin-converting enzyme inhibitors | PharmacologicSubstance | 1,208 | 1,254 | preserve | 1364-1372 | 1364-1372 | T70 | patients | PatientOrDisabledGroup | 1,364 | 1,372 | A1 | Therapy including aspirin, lipid agents (for example, statins), angiotensin-converting enzyme inhibitors, beta-adrenergic blockers, postmenopausal estrogen replacement, and vitamin E should be considered for patients with type 2 diabetes. | 1138-1394 | 1,138 | 1,394 | Therapy including aspirin, lipid agents (for example, statins), @SUBJECT$ , beta-adrenergic blockers, postmenopausal estrogen replacement, and vitamin E should be considered @PREDICAT$ @OBJECT$ with type 2 diabetes. |
Uncommitted | preserve | 1360-1363 | 1360-1363 | T72 | for | TREATS | 1,360 | 1,363 | preserve | 1329-1338 | 1337-1338 | T69 | vitamin E | Lipid | 1,329 | 1,338 | preserve | 1364-1372 | 1364-1372 | T70 | patients | PatientOrDisabledGroup | 1,364 | 1,372 | A2 | Therapy including aspirin, lipid agents (for example, statins), angiotensin-converting enzyme inhibitors, beta-adrenergic blockers, postmenopausal estrogen replacement, and vitamin E should be considered for patients with type 2 diabetes. | 1138-1394 | 1,138 | 1,394 | Therapy including aspirin, lipid agents (for example, statins), angiotensin-converting enzyme inhibitors, beta-adrenergic blockers, postmenopausal estrogen replacement, and @SUBJECT$ should be considered @PREDICAT$ @OBJECT$ with type 2 diabetes. |
Fact | preserve | 1528-1530 | 1528-1530 | T91 | to | higher_than | 1,528 | 1,530 | preserve | 1478-1515 | 1507-1515 | T84 | coronary artery bypass grafting | TherapeuticOrPreventiveProcedure | 1,478 | 1,515 | preserve | 1531-1551 | 1540-1551 | T86 | coronary angioplasty | TherapeuticOrPreventiveProcedure | 1,531 | 1,551 | A3 | In most patients with diabetes who have multivessel coronary artery disease, coronary artery bypass grafting is superior to coronary angioplasty for improving long-term cardiovascular prognosis. | 1395-1607 | 1,395 | 1,607 | In most patients with diabetes who have multivessel coronary artery disease, @SUBJECT$ is superior @PREDICAT$ @OBJECT$ for improving long-term cardiovascular prognosis. |
Uncommitted | preserve | 1360-1363 | 1360-1363 | T72 | for | TREATS | 1,360 | 1,363 | preserve | 1297-1317 | 1306-1317 | T68 | estrogen replacement | TherapeuticOrPreventiveProcedure | 1,297 | 1,317 | preserve | 1364-1372 | 1364-1372 | T70 | patients | PatientOrDisabledGroup | 1,364 | 1,372 | A4 | Therapy including aspirin, lipid agents (for example, statins), angiotensin-converting enzyme inhibitors, beta-adrenergic blockers, postmenopausal estrogen replacement, and vitamin E should be considered for patients with type 2 diabetes. | 1138-1394 | 1,138 | 1,394 | Therapy including aspirin, lipid agents (for example, statins), angiotensin-converting enzyme inhibitors, beta-adrenergic blockers, postmenopausal @SUBJECT$ , and vitamin E should be considered @PREDICAT$ @OBJECT$ with type 2 diabetes. |
Fact | preserve | 101-105 | 101-105 | T6 | with | PROCESS_OF | 101 | 105 | preserve | 106-114 | 106-114 | T4 | diabetes | DiseaseOrSyndrome | 106 | 114 | preserve | 92-100 | 92-100 | T3 | patients | PatientOrDisabledGroup | 92 | 100 | A5 | Approximately 80% of all patients with diabetes die of cardiovascular disease. | 67-145 | 67 | 145 | Approximately 80% of all @OBJECT$ @PREDICAT$ @SUBJECT$ die of cardiovascular disease. |
Uncommitted | preserve | 1360-1363 | 1360-1363 | T72 | for | TREATS | 1,360 | 1,363 | preserve | 1256-1280 | 1272-1280 | T67 | beta-adrenergic blockers | PharmacologicSubstance | 1,256 | 1,280 | preserve | 1364-1372 | 1364-1372 | T70 | patients | PatientOrDisabledGroup | 1,364 | 1,372 | A6 | Therapy including aspirin, lipid agents (for example, statins), angiotensin-converting enzyme inhibitors, beta-adrenergic blockers, postmenopausal estrogen replacement, and vitamin E should be considered for patients with type 2 diabetes. | 1138-1394 | 1,138 | 1,394 | Therapy including aspirin, lipid agents (for example, statins), angiotensin-converting enzyme inhibitors, @SUBJECT$ , postmenopausal estrogen replacement, and vitamin E should be considered @PREDICAT$ @OBJECT$ with type 2 diabetes. |
Fact | preserve | 1528-1530 | 1528-1530 | T90 | to | compared_with | 1,528 | 1,530 | preserve | 1478-1515 | 1507-1515 | T84 | coronary artery bypass grafting | TherapeuticOrPreventiveProcedure | 1,478 | 1,515 | preserve | 1531-1551 | 1540-1551 | T86 | coronary angioplasty | TherapeuticOrPreventiveProcedure | 1,531 | 1,551 | A7 | In most patients with diabetes who have multivessel coronary artery disease, coronary artery bypass grafting is superior to coronary angioplasty for improving long-term cardiovascular prognosis. | 1395-1607 | 1,395 | 1,607 | In most patients with diabetes who have multivessel coronary artery disease, @SUBJECT$ is superior @PREDICAT$ @OBJECT$ for improving long-term cardiovascular prognosis. |
Uncommitted | preserve | 1830-1833 | 1830-1833 | T108 | for | TREATS | 1,830 | 1,833 | preserve | 1757-1777 | 1766-1777 | T103 | coronary angioplasty | TherapeuticOrPreventiveProcedure | 1,757 | 1,777 | preserve | 1838-1846 | 1838-1846 | T105 | patients | PatientOrDisabledGroup | 1,838 | 1,846 | A9 | Urgent coronary angioplasty or thrombolytic therapy should be considered for all patients with diabetes who have acute myocardial infarction. | 1750-1898 | 1,750 | 1,898 | Urgent @SUBJECT$ or thrombolytic therapy should be considered @PREDICAT$ all @OBJECT$ with diabetes who have acute myocardial infarction. |
Uncommitted | preserve | 1830-1833 | 1830-1833 | T108 | for | TREATS | 1,830 | 1,833 | preserve | 1757-1777 | 1766-1777 | T103 | coronary angioplasty | TherapeuticOrPreventiveProcedure | 1,757 | 1,777 | preserve | 1852-1860 | 1852-1860 | T106 | diabetes | DiseaseOrSyndrome | 1,852 | 1,860 | A10 | Urgent coronary angioplasty or thrombolytic therapy should be considered for all patients with diabetes who have acute myocardial infarction. | 1750-1898 | 1,750 | 1,898 | Urgent @SUBJECT$ or thrombolytic therapy should be considered @PREDICAT$ all patients with @OBJECT$ who have acute myocardial infarction. |
Fact | preserve | 1436-1440 | 1436-1440 | T93 | have | PROCESS_OF | 1,436 | 1,440 | preserve | 1441-1476 | 1469-1476 | T83 | multivessel coronary artery disease | DiseaseOrSyndrome | 1,441 | 1,476 | preserve | 1409-1417 | 1409-1417 | T81 | patients | PatientOrDisabledGroup | 1,409 | 1,417 | A11 | In most patients with diabetes who have multivessel coronary artery disease, coronary artery bypass grafting is superior to coronary angioplasty for improving long-term cardiovascular prognosis. | 1395-1607 | 1,395 | 1,607 | In most @OBJECT$ with diabetes who @PREDICAT$ @SUBJECT$ , coronary artery bypass grafting is superior to coronary angioplasty for improving long-term cardiovascular prognosis. |
Uncommitted | preserve | 1360-1363 | 1360-1363 | T72 | for | TREATS | 1,360 | 1,363 | preserve | 1329-1338 | 1337-1338 | T69 | vitamin E | Lipid | 1,329 | 1,338 | preserve | 1378-1393 | 1385-1393 | T71 | type 2 diabetes | DiseaseOrSyndrome | 1,378 | 1,393 | A12 | Therapy including aspirin, lipid agents (for example, statins), angiotensin-converting enzyme inhibitors, beta-adrenergic blockers, postmenopausal estrogen replacement, and vitamin E should be considered for patients with type 2 diabetes. | 1138-1394 | 1,138 | 1,394 | Therapy including aspirin, lipid agents (for example, statins), angiotensin-converting enzyme inhibitors, beta-adrenergic blockers, postmenopausal estrogen replacement, and @SUBJECT$ should be considered @PREDICAT$ patients with @OBJECT$ . |
Fact | preserve | 386-396 | 386-396 | T25 | associated | COEXISTS_WITH | 386 | 396 | preserve | 529-548 | 539-548 | T23 | sedentary lifestyle | Finding | 529 | 548 | preserve | 359-375 | 359-375 | T15 | hyperinsulinemia | DiseaseOrSyndrome | 359 | 375 | A14 | Insulin resistance often leads to hyperinsulinemia, which is associated with hypertension, atherogenic dyslipidemia, left ventricular hypertrophy, impaired fibrinolysis, visceral obesity, and sedentary lifestyle. | 325-549 | 325 | 549 | Insulin resistance often leads to @OBJECT$ , which is @PREDICAT$ with hypertension, atherogenic dyslipidemia, left ventricular hypertrophy, impaired fibrinolysis, visceral obesity, and @SUBJECT$ . |
Fact | preserve | 386-396 | 386-396 | T25 | associated | COEXISTS_WITH | 386 | 396 | preserve | 408-420 | 408-420 | T16 | hypertension | DiseaseOrSyndrome | 408 | 420 | preserve | 359-375 | 359-375 | T15 | hyperinsulinemia | DiseaseOrSyndrome | 359 | 375 | A16 | Insulin resistance often leads to hyperinsulinemia, which is associated with hypertension, atherogenic dyslipidemia, left ventricular hypertrophy, impaired fibrinolysis, visceral obesity, and sedentary lifestyle. | 325-549 | 325 | 549 | Insulin resistance often leads to @OBJECT$ , which is @PREDICAT$ with @SUBJECT$ , atherogenic dyslipidemia, left ventricular hypertrophy, impaired fibrinolysis, visceral obesity, and sedentary lifestyle. |
Uncommitted | preserve | 1360-1363 | 1360-1363 | T72 | for | TREATS | 1,360 | 1,363 | preserve | 1297-1317 | 1306-1317 | T68 | estrogen replacement | TherapeuticOrPreventiveProcedure | 1,297 | 1,317 | preserve | 1378-1393 | 1385-1393 | T71 | type 2 diabetes | DiseaseOrSyndrome | 1,378 | 1,393 | A17 | Therapy including aspirin, lipid agents (for example, statins), angiotensin-converting enzyme inhibitors, beta-adrenergic blockers, postmenopausal estrogen replacement, and vitamin E should be considered for patients with type 2 diabetes. | 1138-1394 | 1,138 | 1,394 | Therapy including aspirin, lipid agents (for example, statins), angiotensin-converting enzyme inhibitors, beta-adrenergic blockers, postmenopausal @SUBJECT$ , and vitamin E should be considered @PREDICAT$ patients with @OBJECT$ . |
Fact | preserve | 386-396 | 386-396 | T25 | associated | COEXISTS_WITH | 386 | 396 | preserve | 434-446 | 434-446 | T17 | dyslipidemia | DiseaseOrSyndrome | 434 | 446 | preserve | 359-375 | 359-375 | T15 | hyperinsulinemia | DiseaseOrSyndrome | 359 | 375 | A18 | Insulin resistance often leads to hyperinsulinemia, which is associated with hypertension, atherogenic dyslipidemia, left ventricular hypertrophy, impaired fibrinolysis, visceral obesity, and sedentary lifestyle. | 325-549 | 325 | 549 | Insulin resistance often leads to @OBJECT$ , which is @PREDICAT$ with hypertension, atherogenic @SUBJECT$ , left ventricular hypertrophy, impaired fibrinolysis, visceral obesity, and sedentary lifestyle. |
Fact | preserve | 1667-1694 | 1689-1694 | T101 | left internal mammary graft | PART_OF | 1,667 | 1,694 | preserve | 1689-1694 | 1689-1694 | T98 | graft | Tissue | 1,689 | 1,694 | preserve | 1667-1688 | 1681-1688 | T97 | left internal mammary | BodyPartOrganOrOrganComponent | 1,667 | 1,688 | A19 | This superiority is mediated in part by the use of a left internal mammary graft to the left anterior descending coronary artery. | 1608-1749 | 1,608 | 1,749 | This superiority is mediated in part by the use of a @OBJECT$ @PREDICAT$ @SUBJECT$ to the left anterior descending coronary artery. |
Fact | preserve | 386-396 | 386-396 | T25 | associated | COEXISTS_WITH | 386 | 396 | preserve | 448-476 | 465-476 | T18 | left ventricular hypertrophy | PathologicFunction | 448 | 476 | preserve | 359-375 | 359-375 | T15 | hyperinsulinemia | DiseaseOrSyndrome | 359 | 375 | A20 | Insulin resistance often leads to hyperinsulinemia, which is associated with hypertension, atherogenic dyslipidemia, left ventricular hypertrophy, impaired fibrinolysis, visceral obesity, and sedentary lifestyle. | 325-549 | 325 | 549 | Insulin resistance often leads to @OBJECT$ , which is @PREDICAT$ with hypertension, atherogenic dyslipidemia, @SUBJECT$ , impaired fibrinolysis, visceral obesity, and sedentary lifestyle. |
Uncommitted | preserve | 1830-1833 | 1830-1833 | T108 | for | TREATS | 1,830 | 1,833 | preserve | 1781-1801 | 1794-1801 | T104 | thrombolytic therapy | TherapeuticOrPreventiveProcedure | 1,781 | 1,801 | preserve | 1838-1846 | 1838-1846 | T105 | patients | PatientOrDisabledGroup | 1,838 | 1,846 | A21 | Urgent coronary angioplasty or thrombolytic therapy should be considered for all patients with diabetes who have acute myocardial infarction. | 1750-1898 | 1,750 | 1,898 | Urgent coronary angioplasty or @SUBJECT$ should be considered @PREDICAT$ all @OBJECT$ with diabetes who have acute myocardial infarction. |
Fact | preserve | 699-703 | 699-703 | T41 | with | PROCESS_OF | 699 | 703 | preserve | 704-712 | 704-712 | T36 | diabetes | DiseaseOrSyndrome | 704 | 712 | preserve | 690-698 | 690-698 | T35 | patients | PatientOrDisabledGroup | 690 | 698 | A22 | Although all these conditions are associated with atherosclerosis and adverse cardiovascular events, the therapeutic efforts in patients with diabetes have focused predominantly on normalizing glucose levels. | 550-776 | 550 | 776 | Although all these conditions are associated with atherosclerosis and adverse cardiovascular events, the therapeutic efforts in @OBJECT$ @PREDICAT$ @SUBJECT$ have focused predominantly on normalizing glucose levels. |
Fact | preserve | 1847-1851 | 1847-1851 | T110 | with | PROCESS_OF | 1,847 | 1,851 | preserve | 1852-1860 | 1852-1860 | T106 | diabetes | DiseaseOrSyndrome | 1,852 | 1,860 | preserve | 1838-1846 | 1838-1846 | T105 | patients | PatientOrDisabledGroup | 1,838 | 1,846 | A23 | Urgent coronary angioplasty or thrombolytic therapy should be considered for all patients with diabetes who have acute myocardial infarction. | 1750-1898 | 1,750 | 1,898 | Urgent coronary angioplasty or thrombolytic therapy should be considered for all @OBJECT$ @PREDICAT$ @SUBJECT$ who have acute myocardial infarction. |
Probable | preserve | 350-355 | 350-355 | T24 | leads | CAUSES | 350 | 355 | preserve | 325-343 | 333-343 | T13 | Insulin resistance | PathologicFunction | 325 | 343 | preserve | 359-375 | 359-375 | T15 | hyperinsulinemia | DiseaseOrSyndrome | 359 | 375 | A24 | Insulin resistance often leads to hyperinsulinemia, which is associated with hypertension, atherogenic dyslipidemia, left ventricular hypertrophy, impaired fibrinolysis, visceral obesity, and sedentary lifestyle. | 325-549 | 325 | 549 | @SUBJECT$ often @PREDICAT$ to @OBJECT$ , which is associated with hypertension, atherogenic dyslipidemia, left ventricular hypertrophy, impaired fibrinolysis, visceral obesity, and sedentary lifestyle. |
Uncommitted | preserve | 1830-1833 | 1830-1833 | T108 | for | TREATS | 1,830 | 1,833 | preserve | 1781-1801 | 1794-1801 | T104 | thrombolytic therapy | TherapeuticOrPreventiveProcedure | 1,781 | 1,801 | preserve | 1852-1860 | 1852-1860 | T106 | diabetes | DiseaseOrSyndrome | 1,852 | 1,860 | A25 | Urgent coronary angioplasty or thrombolytic therapy should be considered for all patients with diabetes who have acute myocardial infarction. | 1750-1898 | 1,750 | 1,898 | Urgent coronary angioplasty or @SUBJECT$ should be considered @PREDICAT$ all patients with @OBJECT$ who have acute myocardial infarction. |
Fact | preserve | 1418-1422 | 1418-1422 | T92 | with | PROCESS_OF | 1,418 | 1,422 | preserve | 1423-1431 | 1423-1431 | T82 | diabetes | DiseaseOrSyndrome | 1,423 | 1,431 | preserve | 1409-1417 | 1409-1417 | T81 | patients | PatientOrDisabledGroup | 1,409 | 1,417 | A26 | In most patients with diabetes who have multivessel coronary artery disease, coronary artery bypass grafting is superior to coronary angioplasty for improving long-term cardiovascular prognosis. | 1395-1607 | 1,395 | 1,607 | In most @OBJECT$ @PREDICAT$ @SUBJECT$ who have multivessel coronary artery disease, coronary artery bypass grafting is superior to coronary angioplasty for improving long-term cardiovascular prognosis. |
Fact | preserve | 386-396 | 386-396 | T25 | associated | COEXISTS_WITH | 386 | 396 | preserve | 516-523 | 516-523 | T22 | obesity | DiseaseOrSyndrome | 516 | 523 | preserve | 359-375 | 359-375 | T15 | hyperinsulinemia | DiseaseOrSyndrome | 359 | 375 | A27 | Insulin resistance often leads to hyperinsulinemia, which is associated with hypertension, atherogenic dyslipidemia, left ventricular hypertrophy, impaired fibrinolysis, visceral obesity, and sedentary lifestyle. | 325-549 | 325 | 549 | Insulin resistance often leads to @OBJECT$ , which is @PREDICAT$ with hypertension, atherogenic dyslipidemia, left ventricular hypertrophy, impaired fibrinolysis, visceral @SUBJECT$ , and sedentary lifestyle. |
Uncommitted | preserve | 1360-1363 | 1360-1363 | T72 | for | TREATS | 1,360 | 1,363 | preserve | 1256-1280 | 1272-1280 | T67 | beta-adrenergic blockers | PharmacologicSubstance | 1,256 | 1,280 | preserve | 1378-1393 | 1385-1393 | T71 | type 2 diabetes | DiseaseOrSyndrome | 1,378 | 1,393 | A28 | Therapy including aspirin, lipid agents (for example, statins), angiotensin-converting enzyme inhibitors, beta-adrenergic blockers, postmenopausal estrogen replacement, and vitamin E should be considered for patients with type 2 diabetes. | 1138-1394 | 1,138 | 1,394 | Therapy including aspirin, lipid agents (for example, statins), angiotensin-converting enzyme inhibitors, @SUBJECT$ , postmenopausal estrogen replacement, and vitamin E should be considered @PREDICAT$ patients with @OBJECT$ . |
Fact | preserve | 1373-1377 | 1373-1377 | T76 | with | PROCESS_OF | 1,373 | 1,377 | preserve | 1378-1393 | 1385-1393 | T71 | type 2 diabetes | DiseaseOrSyndrome | 1,378 | 1,393 | preserve | 1364-1372 | 1364-1372 | T70 | patients | PatientOrDisabledGroup | 1,364 | 1,372 | A29 | Therapy including aspirin, lipid agents (for example, statins), angiotensin-converting enzyme inhibitors, beta-adrenergic blockers, postmenopausal estrogen replacement, and vitamin E should be considered for patients with type 2 diabetes. | 1138-1394 | 1,138 | 1,394 | Therapy including aspirin, lipid agents (for example, statins), angiotensin-converting enzyme inhibitors, beta-adrenergic blockers, postmenopausal estrogen replacement, and vitamin E should be considered for @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Uncommitted | preserve | 1360-1363 | 1360-1363 | T72 | for | TREATS | 1,360 | 1,363 | preserve | 1208-1254 | 1244-1254 | T66 | angiotensin-converting enzyme inhibitors | PharmacologicSubstance | 1,208 | 1,254 | preserve | 1378-1393 | 1385-1393 | T71 | type 2 diabetes | DiseaseOrSyndrome | 1,378 | 1,393 | A30 | Therapy including aspirin, lipid agents (for example, statins), angiotensin-converting enzyme inhibitors, beta-adrenergic blockers, postmenopausal estrogen replacement, and vitamin E should be considered for patients with type 2 diabetes. | 1138-1394 | 1,138 | 1,394 | Therapy including aspirin, lipid agents (for example, statins), @SUBJECT$ , beta-adrenergic blockers, postmenopausal estrogen replacement, and vitamin E should be considered @PREDICAT$ patients with @OBJECT$ . |
Fact | preserve | 1616-1618 | 1616-1618 | T84 | in | TREATS | 1,616 | 1,618 | preserve | 1606-1615 | 1606-1615 | T81 | therapies | TherapeuticOrPreventiveProcedure | 1,606 | 1,615 | preserve | 1633-1646 | 1639-1646 | T83 | heart failure | DiseaseOrSyndrome | 1,633 | 1,646 | A1 | The Valsartan in Heart Failure Trial (Val-HeFT) has been designed to test the efficacy and safety of the AT(1) receptor blocker (ARB) valsartan in combination with ACE inhibitors and all other prescribed therapies in patients with heart failure. | 1384-1647 | 1,384 | 1,647 | The Valsartan in Heart Failure Trial (Val-HeFT) has been designed to test the efficacy and safety of the AT(1) receptor blocker (ARB) valsartan in combination with ACE inhibitors and all other prescribed @SUBJECT$ @PREDICAT$ patients with @OBJECT$ . |
Fact | preserve | 1616-1618 | 1616-1618 | T84 | in | TREATS | 1,616 | 1,618 | preserve | 1560-1574 | 1564-1574 | T79 | ACE inhibitors | PharmacologicSubstance | 1,560 | 1,574 | preserve | 1633-1646 | 1639-1646 | T83 | heart failure | DiseaseOrSyndrome | 1,633 | 1,646 | A2 | The Valsartan in Heart Failure Trial (Val-HeFT) has been designed to test the efficacy and safety of the AT(1) receptor blocker (ARB) valsartan in combination with ACE inhibitors and all other prescribed therapies in patients with heart failure. | 1384-1647 | 1,384 | 1,647 | The Valsartan in Heart Failure Trial (Val-HeFT) has been designed to test the efficacy and safety of the AT(1) receptor blocker (ARB) valsartan in combination with @SUBJECT$ and all other prescribed therapies @PREDICAT$ patients with @OBJECT$ . |
Fact | preserve | 1343-1353 | 1343-1353 | T70 | inhibition | DISRUPTS | 1,343 | 1,353 | preserve | 1333-1336 | 1333-1336 | T66 | ACE | AminoAcidPeptideOrProtein | 1,333 | 1,336 | preserve | 1285-1301 | 1285-1301 | T63 | vasoconstriction | OrganOrTissueFunction | 1,285 | 1,301 | A3 | Persistent angiotensin-induced vasoconstriction and endocrine effects, despite ACE inhibition, is one possible explanation. | 1248-1383 | 1,248 | 1,383 | Persistent angiotensin-induced @OBJECT$ and endocrine effects, despite @SUBJECT$ @PREDICAT$ , is one possible explanation. |
Fact | preserve | 1628-1632 | 1628-1632 | T86 | with | PROCESS_OF | 1,628 | 1,632 | preserve | 1633-1646 | 1639-1646 | T83 | heart failure | DiseaseOrSyndrome | 1,633 | 1,646 | preserve | 1619-1627 | 1619-1627 | T82 | patients | PatientOrDisabledGroup | 1,619 | 1,627 | A4 | The Valsartan in Heart Failure Trial (Val-HeFT) has been designed to test the efficacy and safety of the AT(1) receptor blocker (ARB) valsartan in combination with ACE inhibitors and all other prescribed therapies in patients with heart failure. | 1384-1647 | 1,384 | 1,647 | The Valsartan in Heart Failure Trial (Val-HeFT) has been designed to test the efficacy and safety of the AT(1) receptor blocker (ARB) valsartan in combination with ACE inhibitors and all other prescribed therapies in @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 1616-1618 | 1616-1618 | T84 | in | TREATS | 1,616 | 1,618 | preserve | 1560-1574 | 1564-1574 | T79 | ACE inhibitors | PharmacologicSubstance | 1,560 | 1,574 | preserve | 1619-1627 | 1619-1627 | T82 | patients | PatientOrDisabledGroup | 1,619 | 1,627 | A5 | The Valsartan in Heart Failure Trial (Val-HeFT) has been designed to test the efficacy and safety of the AT(1) receptor blocker (ARB) valsartan in combination with ACE inhibitors and all other prescribed therapies in patients with heart failure. | 1384-1647 | 1,384 | 1,647 | The Valsartan in Heart Failure Trial (Val-HeFT) has been designed to test the efficacy and safety of the AT(1) receptor blocker (ARB) valsartan in combination with @SUBJECT$ and all other prescribed therapies @PREDICAT$ @OBJECT$ with heart failure. |
Fact | preserve | 1188-1246 | 1188-1197 | T58 | magnitude of these benefits has been disappointingly small | ISA | 1,188 | 1,246 | preserve | 1241-1246 | 1241-1246 | T57 | small | QuantitativeConcept | 1,241 | 1,246 | preserve | 1188-1197 | 1188-1197 | T55 | magnitude | QuantitativeConcept | 1,188 | 1,197 | A6 | Angiotensin-converting enzyme (ACE) inhibitors have exerted favorable effects on both quality of life and mortality, but the magnitude of these benefits has been disappointingly small. | 1051-1247 | 1,051 | 1,247 | Angiotensin-converting enzyme (ACE) inhibitors have exerted favorable effects on both quality of life and mortality, but the @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Probable | preserve | 999-1005 | 999-1005 | T49 | reduce | PREVENTS | 999 | 1,005 | preserve | 989-994 | 989-994 | T46 | drugs | PharmacologicSubstance | 989 | 994 | preserve | 1006-1014 | 1006-1014 | T47 | symptoms | SignOrSymptom | 1,006 | 1,014 | A7 | Certain inotropic drugs may reduce symptoms but shorten life expectancy. | 971-1050 | 971 | 1,050 | Certain inotropic @SUBJECT$ may @PREDICAT$ @OBJECT$ but shorten life expectancy. |
Fact | preserve | 1616-1618 | 1616-1618 | T84 | in | TREATS | 1,616 | 1,618 | preserve | 1606-1615 | 1606-1615 | T81 | therapies | TherapeuticOrPreventiveProcedure | 1,606 | 1,615 | preserve | 1619-1627 | 1619-1627 | T82 | patients | PatientOrDisabledGroup | 1,619 | 1,627 | A9 | The Valsartan in Heart Failure Trial (Val-HeFT) has been designed to test the efficacy and safety of the AT(1) receptor blocker (ARB) valsartan in combination with ACE inhibitors and all other prescribed therapies in patients with heart failure. | 1384-1647 | 1,384 | 1,647 | The Valsartan in Heart Failure Trial (Val-HeFT) has been designed to test the efficacy and safety of the AT(1) receptor blocker (ARB) valsartan in combination with ACE inhibitors and all other prescribed @SUBJECT$ @PREDICAT$ @OBJECT$ with heart failure. |
Fact | preserve | 2214-2223 | 2214-2223 | T133 | treatment | TREATS | 2,214 | 2,223 | preserve | 2196-2209 | 2200-2209 | T128 | ACE inhibitor | PharmacologicSubstance | 2,196 | 2,209 | preserve | 2227-2240 | 2233-2240 | T130 | heart failure | DiseaseOrSyndrome | 2,227 | 2,240 | A2 | High doses of angiotensin-converting enzyme (ACE) inhibitors should be reserved for dialysis patients who have hypertension that cannot be controlled by other agents, or who require an ACE inhibitor for treatment of heart failure. | 1992-2241 | 1,992 | 2,241 | High doses of angiotensin-converting enzyme (ACE) inhibitors should be reserved for dialysis patients who have hypertension that cannot be controlled by other agents, or who require an @SUBJECT$ for @PREDICAT$ of @OBJECT$ . |
Fact | preserve | 1570-1574 | 1570-1574 | T99 | with | PROCESS_OF | 1,570 | 1,574 | preserve | 1575-1582 | 1575-1582 | T90 | anaemia | DiseaseOrSyndrome | 1,575 | 1,582 | preserve | 1561-1569 | 1561-1569 | T89 | patients | PatientOrDisabledGroup | 1,561 | 1,569 | A3 | L-Carnitine supplementation may be appropriate in some patients with anaemia of chronic renal failure (CRF) unresponsive to, or requiring large doses of, epoetin. | 1500-1674 | 1,500 | 1,674 | L-Carnitine supplementation may be appropriate in some @OBJECT$ @PREDICAT$ @SUBJECT$ of chronic renal failure (CRF) unresponsive to, or requiring large doses of, epoetin. |
Fact | preserve | 2110-2114 | 2110-2114 | T132 | have | PROCESS_OF | 2,110 | 2,114 | preserve | 2115-2127 | 2115-2127 | T126 | hypertension | DiseaseOrSyndrome | 2,115 | 2,127 | preserve | 2097-2105 | 2097-2105 | T125 | patients | PatientOrDisabledGroup | 2,097 | 2,105 | A4 | High doses of angiotensin-converting enzyme (ACE) inhibitors should be reserved for dialysis patients who have hypertension that cannot be controlled by other agents, or who require an ACE inhibitor for treatment of heart failure. | 1992-2241 | 1,992 | 2,241 | High doses of angiotensin-converting enzyme (ACE) inhibitors should be reserved for dialysis @OBJECT$ who @PREDICAT$ @SUBJECT$ that cannot be controlled by other agents, or who require an ACE inhibitor for treatment of heart failure. |
Fact | preserve | 1978-1990 | 1982-1990 | T119 | CRF patients | PROCESS_OF | 1,978 | 1,990 | preserve | 1978-1981 | 1978-1981 | T117 | CRF | DiseaseOrSyndrome | 1,978 | 1,981 | preserve | 1982-1990 | 1982-1990 | T118 | patients | PatientOrDisabledGroup | 1,982 | 1,990 | A6 | Recent animal studies indicate that the combination of epoetin and insulin-like growth factor 1 might be beneficial in CRF patients. | 1847-1991 | 1,847 | 1,991 | Recent animal studies indicate that the combination of epoetin and insulin-like growth factor 1 might be beneficial in @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 1500-1533 | 1518-1533 | T97 | L-Carnitine supplementation | USES | 1,500 | 1,533 | preserve | 1518-1533 | 1518-1533 | T87 | supplementation | TherapeuticOrPreventiveProcedure | 1,518 | 1,533 | preserve | 1500-1511 | 1500-1511 | T86 | L-Carnitine | OrganicChemical | 1,500 | 1,511 | A8 | L-Carnitine supplementation may be appropriate in some patients with anaemia of chronic renal failure (CRF) unresponsive to, or requiring large doses of, epoetin. | 1500-1674 | 1,500 | 1,674 | @OBJECT$ @PREDICAT$ @SUBJECT$ may be appropriate in some patients with anaemia of chronic renal failure (CRF) unresponsive to, or requiring large doses of, epoetin. |
Fact | preserve | 355-364 | 355-364 | T26 | receiving | ADMINISTERED_TO | 355 | 364 | preserve | 365-372 | 365-372 | T24 | epoetin | AminoAcidPeptideOrProtein | 365 | 372 | preserve | 346-354 | 346-354 | T23 | patients | PatientOrDisabledGroup | 346 | 354 | A9 | Iron supplementation is currently the most widely used form of adjuvant therapy; intravenous (i.v.) iron is required by the majority of haemodialysis patients receiving epoetin. | 184-373 | 184 | 373 | Iron supplementation is currently the most widely used form of adjuvant therapy; intravenous (i.v.) iron is required by the majority of haemodialysis @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Possible | preserve | 1975-1977 | 1975-1977 | T120 | in | TREATS | 1,975 | 1,977 | preserve | 1908-1915 | 1908-1915 | T115 | epoetin | AminoAcidPeptideOrProtein | 1,908 | 1,915 | preserve | 1982-1990 | 1982-1990 | T118 | patients | PatientOrDisabledGroup | 1,982 | 1,990 | A10 | Recent animal studies indicate that the combination of epoetin and insulin-like growth factor 1 might be beneficial in CRF patients. | 1847-1991 | 1,847 | 1,991 | Recent animal studies indicate that the combination of @SUBJECT$ and insulin-like growth factor 1 might be beneficial @PREDICAT$ CRF @OBJECT$ . |
Fact | preserve | 1017-1032 | 1025-1032 | T66 | epoetin therapy | ISA | 1,017 | 1,032 | preserve | 1017-1024 | 1017-1024 | T61 | epoetin | AminoAcidPeptideOrProtein | 1,017 | 1,024 | preserve | 1025-1032 | 1025-1032 | T62 | therapy | TherapeuticOrPreventiveProcedure | 1,025 | 1,032 | A11 | Vitamin B6 requirements are increased during epoetin therapy, and supplementation at a dose of 100-150 mg/week is recommended. | 965-1098 | 965 | 1,098 | Vitamin B6 requirements are increased during @SUBJECT$ @PREDICAT$ @OBJECT$ , and supplementation at a dose of 100-150 mg/week is recommended. |
Possible | preserve | 903-910 | 903-910 | T57 | improve | TREATS | 903 | 910 | preserve | 844-856 | 844-856 | T51 | alfacalcidol | PharmacologicSubstance | 844 | 856 | preserve | 911-918 | 911-918 | T53 | anaemia | DiseaseOrSyndrome | 911 | 918 | A12 | The active vitamin D metabolites alfacalcidol and calcitriol may, under some circumstances, improve anaemia and reduce epoetin dosage requirements. | 805-964 | 805 | 964 | The active vitamin D metabolites @SUBJECT$ and calcitriol may, under some circumstances, @PREDICAT$ @OBJECT$ and reduce epoetin dosage requirements. |
Fact | preserve | 119-126 | 119-126 | T12 | treated | TREATS | 119 | 126 | preserve | 132-139 | 132-139 | T8 | epoetin | AminoAcidPeptideOrProtein | 132 | 139 | preserve | 104-112 | 104-112 | T7 | patients | PatientOrDisabledGroup | 104 | 112 | A13 | Adjuvant therapy may allow patients being treated with epoetin to derive greater clinical benefits. | 77-183 | 77 | 183 | Adjuvant therapy may allow @OBJECT$ being @PREDICAT$ with @SUBJECT$ to derive greater clinical benefits. |
Fact | preserve | 2078-2081 | 2078-2081 | T131 | for | TREATS | 2,078 | 2,081 | preserve | 2012-2058 | 2048-2058 | T123 | angiotensin-converting enzyme (ACE) inhibitors | PharmacologicSubstance | 2,012 | 2,058 | preserve | 2115-2127 | 2115-2127 | T126 | hypertension | DiseaseOrSyndrome | 2,115 | 2,127 | A14 | High doses of angiotensin-converting enzyme (ACE) inhibitors should be reserved for dialysis patients who have hypertension that cannot be controlled by other agents, or who require an ACE inhibitor for treatment of heart failure. | 1992-2241 | 1,992 | 2,241 | High doses of @SUBJECT$ should be reserved @PREDICAT$ dialysis patients who have @OBJECT$ that cannot be controlled by other agents, or who require an ACE inhibitor for treatment of heart failure. |
Fact | preserve | 2078-2081 | 2078-2081 | T131 | for | TREATS | 2,078 | 2,081 | preserve | 2012-2058 | 2048-2058 | T123 | angiotensin-converting enzyme (ACE) inhibitors | PharmacologicSubstance | 2,012 | 2,058 | preserve | 2097-2105 | 2097-2105 | T125 | patients | PatientOrDisabledGroup | 2,097 | 2,105 | A15 | High doses of angiotensin-converting enzyme (ACE) inhibitors should be reserved for dialysis patients who have hypertension that cannot be controlled by other agents, or who require an ACE inhibitor for treatment of heart failure. | 1992-2241 | 1,992 | 2,241 | High doses of @SUBJECT$ should be reserved @PREDICAT$ dialysis @OBJECT$ who have hypertension that cannot be controlled by other agents, or who require an ACE inhibitor for treatment of heart failure. |
Probable | preserve | 1553-1555 | 1553-1555 | T98 | in | TREATS | 1,553 | 1,555 | preserve | 1518-1533 | 1518-1533 | T87 | supplementation | TherapeuticOrPreventiveProcedure | 1,518 | 1,533 | preserve | 1561-1569 | 1561-1569 | T89 | patients | PatientOrDisabledGroup | 1,561 | 1,569 | A16 | L-Carnitine supplementation may be appropriate in some patients with anaemia of chronic renal failure (CRF) unresponsive to, or requiring large doses of, epoetin. | 1500-1674 | 1,500 | 1,674 | L-Carnitine @SUBJECT$ may be appropriate @PREDICAT$ some @OBJECT$ with anaemia of chronic renal failure (CRF) unresponsive to, or requiring large doses of, epoetin. |
Uncommitted | preserve | 37-39 | 37-39 | T5 | in | TREATS | 37 | 39 | preserve | 20-36 | 29-36 | T2 | adjuvant therapy | TherapeuticOrPreventiveProcedure | 20 | 36 | preserve | 40-48 | 40-48 | T3 | patients | PatientOrDisabledGroup | 40 | 48 | A17 | Is there a role for adjuvant therapy in patients being treated with epoetin? | 0-76 | 0 | 76 | Is there a role for @SUBJECT$ @PREDICAT$ @OBJECT$ being treated with epoetin? |
Probable | preserve | 1553-1555 | 1553-1555 | T98 | in | TREATS | 1,553 | 1,555 | preserve | 1518-1533 | 1518-1533 | T87 | supplementation | TherapeuticOrPreventiveProcedure | 1,518 | 1,533 | preserve | 1575-1582 | 1575-1582 | T90 | anaemia | DiseaseOrSyndrome | 1,575 | 1,582 | A18 | L-Carnitine supplementation may be appropriate in some patients with anaemia of chronic renal failure (CRF) unresponsive to, or requiring large doses of, epoetin. | 1500-1674 | 1,500 | 1,674 | L-Carnitine @SUBJECT$ may be appropriate @PREDICAT$ some patients with @OBJECT$ of chronic renal failure (CRF) unresponsive to, or requiring large doses of, epoetin. |
Fact | preserve | 184-204 | 189-204 | T25 | Iron supplementation | USES | 184 | 204 | preserve | 189-204 | 189-204 | T14 | supplementation | TherapeuticOrPreventiveProcedure | 189 | 204 | preserve | 184-188 | 184-188 | T13 | Iron | BiologicallyActiveSubstance | 184 | 188 | A19 | Iron supplementation is currently the most widely used form of adjuvant therapy; intravenous (i.v.) iron is required by the majority of haemodialysis patients receiving epoetin. | 184-373 | 184 | 373 | @OBJECT$ @PREDICAT$ @SUBJECT$ is currently the most widely used form of adjuvant therapy; intravenous (i.v.) iron is required by the majority of haemodialysis patients receiving epoetin. |
Fact | preserve | 1472-1476 | 1472-1476 | T85 | with | PROCESS_OF | 1,472 | 1,476 | preserve | 1477-1498 | 1477-1498 | T83 | hyperhomocysteinaemia | DiseaseOrSyndrome | 1,477 | 1,498 | preserve | 1463-1471 | 1463-1471 | T82 | patients | PatientOrDisabledGroup | 1,463 | 1,471 | A20 | Low doses (2-3 mg/week) should normally be sufficient to maintain optimal folic acid stores in epoetin-treated patients, although higher doses are necessary for patients with hyperhomocysteinaemia. | 1290-1499 | 1,290 | 1,499 | Low doses (2-3 mg/week) should normally be sufficient to maintain optimal folic acid stores in epoetin-treated patients, although higher doses are necessary for @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Possible | preserve | 903-910 | 903-910 | T57 | improve | TREATS | 903 | 910 | preserve | 861-871 | 861-871 | T52 | calcitriol | Hormone | 861 | 871 | preserve | 911-918 | 911-918 | T53 | anaemia | DiseaseOrSyndrome | 911 | 918 | A21 | The active vitamin D metabolites alfacalcidol and calcitriol may, under some circumstances, improve anaemia and reduce epoetin dosage requirements. | 805-964 | 805 | 964 | The active vitamin D metabolites alfacalcidol and @SUBJECT$ may, under some circumstances, @PREDICAT$ @OBJECT$ and reduce epoetin dosage requirements. |
Possible | preserve | 1975-1977 | 1975-1977 | T120 | in | TREATS | 1,975 | 1,977 | preserve | 1908-1915 | 1908-1915 | T115 | epoetin | AminoAcidPeptideOrProtein | 1,908 | 1,915 | preserve | 1978-1981 | 1978-1981 | T117 | CRF | DiseaseOrSyndrome | 1,978 | 1,981 | A22 | Recent animal studies indicate that the combination of epoetin and insulin-like growth factor 1 might be beneficial in CRF patients. | 1847-1991 | 1,847 | 1,991 | Recent animal studies indicate that the combination of @SUBJECT$ and insulin-like growth factor 1 might be beneficial @PREDICAT$ @OBJECT$ patients. |
Fact | preserve | 1824-1828 | 1824-1828 | T111 | with | PROCESS_OF | 1,824 | 1,828 | preserve | 1839-1845 | 1839-1845 | T109 | kidney | ClinicalAttribute | 1,839 | 1,845 | preserve | 1800-1803 | 1800-1803 | T106 | men | PopulationGroup | 1,800 | 1,803 | A23 | Androgens potentially could reduce epoetin costs in countries with limited resources, but should only be used in men older than 50 years with a remnant kidney. | 1675-1846 | 1,675 | 1,846 | Androgens potentially could reduce epoetin costs in countries with limited resources, but should only be used in @OBJECT$ older than 50 years @PREDICAT$ a remnant @SUBJECT$ . |
Fact | preserve | 716-718 | 716-718 | T43 | in | TREATS | 716 | 718 | preserve | 687-694 | 687-694 | T38 | therapy | TherapeuticOrPreventiveProcedure | 687 | 694 | preserve | 739-749 | 747-749 | T41 | Type II DM | DiseaseOrSyndrome | 739 | 749 | A2 | This 11-year study is comparing conventional therapy to intensive therapy in patients with Type II DM. | 636-750 | 636 | 750 | This 11-year study is comparing conventional @SUBJECT$ to intensive therapy @PREDICAT$ patients with @OBJECT$ . |
Fact | preserve | 907-916 | 907-916 | T63 | treatment | TREATS | 907 | 916 | preserve | 867-874 | 867-874 | T54 | insulin | AminoAcidPeptideOrProtein | 867 | 874 | preserve | 921-931 | 929-931 | T58 | Type II DM | DiseaseOrSyndrome | 921 | 931 | A3 | The American Diabetes Association's (ADA) guidelines state that either sulfonylureas, metformin, acarbose, or insulin can be used as first-line treatment for Type II DM; however, oral agents can be attempted first in most patients. | 751-1000 | 751 | 1,000 | The American Diabetes Association's (ADA) guidelines state that either sulfonylureas, metformin, acarbose, or @SUBJECT$ can be used as first-line @PREDICAT$ for @OBJECT$ ; however, oral agents can be attempted first in most patients. |
Fact | preserve | 716-718 | 716-718 | T43 | in | TREATS | 716 | 718 | preserve | 708-715 | 708-715 | T39 | therapy | TherapeuticOrPreventiveProcedure | 708 | 715 | preserve | 719-727 | 719-727 | T40 | patients | PatientOrDisabledGroup | 719 | 727 | A4 | This 11-year study is comparing conventional therapy to intensive therapy in patients with Type II DM. | 636-750 | 636 | 750 | This 11-year study is comparing conventional therapy to intensive @SUBJECT$ @PREDICAT$ @OBJECT$ with Type II DM. |
Fact | preserve | 907-916 | 907-916 | T63 | treatment | TREATS | 907 | 916 | preserve | 843-852 | 843-852 | T52 | metformin | OrganicChemical | 843 | 852 | preserve | 921-931 | 929-931 | T58 | Type II DM | DiseaseOrSyndrome | 921 | 931 | A5 | The American Diabetes Association's (ADA) guidelines state that either sulfonylureas, metformin, acarbose, or insulin can be used as first-line treatment for Type II DM; however, oral agents can be attempted first in most patients. | 751-1000 | 751 | 1,000 | The American Diabetes Association's (ADA) guidelines state that either sulfonylureas, @SUBJECT$ , acarbose, or insulin can be used as first-line @PREDICAT$ for @OBJECT$ ; however, oral agents can be attempted first in most patients. |
Fact | preserve | 716-718 | 716-718 | T43 | in | TREATS | 716 | 718 | preserve | 708-715 | 708-715 | T39 | therapy | TherapeuticOrPreventiveProcedure | 708 | 715 | preserve | 739-749 | 747-749 | T41 | Type II DM | DiseaseOrSyndrome | 739 | 749 | A6 | This 11-year study is comparing conventional therapy to intensive therapy in patients with Type II DM. | 636-750 | 636 | 750 | This 11-year study is comparing conventional therapy to intensive @SUBJECT$ @PREDICAT$ patients with @OBJECT$ . |
Fact | preserve | 728-732 | 728-732 | T45 | with | PROCESS_OF | 728 | 732 | preserve | 739-749 | 747-749 | T41 | Type II DM | DiseaseOrSyndrome | 739 | 749 | preserve | 719-727 | 719-727 | T40 | patients | PatientOrDisabledGroup | 719 | 727 | A7 | This 11-year study is comparing conventional therapy to intensive therapy in patients with Type II DM. | 636-750 | 636 | 750 | This 11-year study is comparing conventional therapy to intensive therapy in @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 506-510 | 506-510 | T30 | with | PROCESS_OF | 506 | 510 | preserve | 511-521 | 519-521 | T29 | Type II DM | DiseaseOrSyndrome | 511 | 521 | preserve | 497-505 | 497-505 | T28 | patients | PatientOrDisabledGroup | 497 | 505 | A8 | Still, the current standard of practice is to attempt to attain glycemic goals in patients with Type II DM. | 409-522 | 409 | 522 | Still, the current standard of practice is to attempt to attain glycemic goals in @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 907-916 | 907-916 | T63 | treatment | TREATS | 907 | 916 | preserve | 828-841 | 828-841 | T51 | sulfonylureas | OrganicChemical | 828 | 841 | preserve | 921-931 | 929-931 | T58 | Type II DM | DiseaseOrSyndrome | 921 | 931 | A9 | The American Diabetes Association's (ADA) guidelines state that either sulfonylureas, metformin, acarbose, or insulin can be used as first-line treatment for Type II DM; however, oral agents can be attempted first in most patients. | 751-1000 | 751 | 1,000 | The American Diabetes Association's (ADA) guidelines state that either @SUBJECT$ , metformin, acarbose, or insulin can be used as first-line @PREDICAT$ for @OBJECT$ ; however, oral agents can be attempted first in most patients. |
Fact | preserve | 316-318 | 316-318 | T22 | in | COEXISTS_WITH | 316 | 318 | preserve | 268-281 | 268-281 | T14 | complications | PathologicFunction | 268 | 281 | preserve | 319-329 | 327-329 | T17 | Type II DM | DiseaseOrSyndrome | 319 | 329 | A10 | Currently, no data exist showing improved outcomes or reduced macrovascular complications with tight glycemic control in Type II DM, and only minimal data shows a reduction of microvascular complications. | 186-408 | 186 | 408 | Currently, no data exist showing improved outcomes or reduced macrovascular @SUBJECT$ with tight glycemic control @PREDICAT$ @OBJECT$ , and only minimal data shows a reduction of microvascular complications. |
Fact | preserve | 664-673 | 664-673 | T42 | comparing | compared_with | 664 | 673 | preserve | 687-694 | 687-694 | T38 | therapy | TherapeuticOrPreventiveProcedure | 687 | 694 | preserve | 708-715 | 708-715 | T39 | therapy | TherapeuticOrPreventiveProcedure | 708 | 715 | A11 | This 11-year study is comparing conventional therapy to intensive therapy in patients with Type II DM. | 636-750 | 636 | 750 | This 11-year study is @PREDICAT$ conventional @SUBJECT$ to intensive @OBJECT$ in patients with Type II DM. |
Fact | preserve | 907-916 | 907-916 | T63 | treatment | TREATS | 907 | 916 | preserve | 854-862 | 854-862 | T53 | acarbose | Carbohydrate | 854 | 862 | preserve | 921-931 | 929-931 | T58 | Type II DM | DiseaseOrSyndrome | 921 | 931 | A12 | The American Diabetes Association's (ADA) guidelines state that either sulfonylureas, metformin, acarbose, or insulin can be used as first-line treatment for Type II DM; however, oral agents can be attempted first in most patients. | 751-1000 | 751 | 1,000 | The American Diabetes Association's (ADA) guidelines state that either sulfonylureas, metformin, @SUBJECT$ , or insulin can be used as first-line @PREDICAT$ for @OBJECT$ ; however, oral agents can be attempted first in most patients. |
Fact | preserve | 716-718 | 716-718 | T43 | in | TREATS | 716 | 718 | preserve | 687-694 | 687-694 | T38 | therapy | TherapeuticOrPreventiveProcedure | 687 | 694 | preserve | 719-727 | 719-727 | T40 | patients | PatientOrDisabledGroup | 719 | 727 | A13 | This 11-year study is comparing conventional therapy to intensive therapy in patients with Type II DM. | 636-750 | 636 | 750 | This 11-year study is comparing conventional @SUBJECT$ to intensive therapy @PREDICAT$ @OBJECT$ with Type II DM. |
Fact | preserve | 2052-2073 | 2066-2073 | T106 | antibacterial therapy | USES | 2,052 | 2,073 | preserve | 2066-2073 | 2066-2073 | T103 | therapy | TherapeuticOrPreventiveProcedure | 2,066 | 2,073 | preserve | 2052-2065 | 2052-2065 | T102 | antibacterial | Antibiotic | 2,052 | 2,065 | A2 | Future large-scale clinical trials are needed to further evaluate the evidence of causality and the efficacy of antibacterial therapy for coronary artery disease. | 1926-2102 | 1,926 | 2,102 | Future large-scale clinical trials are needed to further evaluate the evidence of causality and the efficacy of @OBJECT$ @PREDICAT$ @SUBJECT$ for coronary artery disease. |
Possible | preserve | 357-365 | 357-365 | T25 | modulate | AFFECTS | 357 | 365 | preserve | 323-340 | 331-340 | T20 | chronic infection | DiseaseOrSyndrome | 323 | 340 | preserve | 378-387 | 378-387 | T21 | processes | PhenomenonOrProcess | 378 | 387 | A3 | With this awareness, the possibility that acute or chronic infection may initiate or modulate these processes in an active area of investigation. | 266-423 | 266 | 423 | With this awareness, the possibility that acute or @SUBJECT$ may initiate or @PREDICAT$ these @OBJECT$ in an active area of investigation. |
Fact | preserve | 1626-1649 | 1640-1649 | T89 | antibacterial treatment | USES | 1,626 | 1,649 | preserve | 1640-1649 | 1640-1649 | T83 | treatment | TherapeuticOrPreventiveProcedure | 1,640 | 1,649 | preserve | 1626-1639 | 1626-1639 | T82 | antibacterial | Antibiotic | 1,626 | 1,639 | A4 | Finally, recent pilot trials have demonstrated that macrolide antibacterial treatment directed against C. pneumoniae reduces the risk of recurrent coronary events. | 1558-1733 | 1,558 | 1,733 | Finally, recent pilot trials have demonstrated that macrolide @OBJECT$ @PREDICAT$ @SUBJECT$ directed against C. pneumoniae reduces the risk of recurrent coronary events. |
Fact | preserve | 1330-1353 | 1346-1353 | T71 | coronary artery plaques | LOCATION_OF | 1,330 | 1,353 | preserve | 1330-1345 | 1339-1345 | T69 | coronary artery | BodyPartOrganOrOrganComponent | 1,330 | 1,345 | preserve | 1346-1353 | 1346-1353 | T70 | plaques | AcquiredAbnormality | 1,346 | 1,353 | A5 | In addition, pathological examinations have demonstrated the presence of infectious organisms in coronary artery plaques. | 1227-1354 | 1,227 | 1,354 | In addition, pathological examinations have demonstrated the presence of infectious organisms in @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Possible | preserve | 50-54 | 50-54 | T9 | role | AFFECTS | 50 | 54 | preserve | 58-67 | 58-67 | T6 | infection | DiseaseOrSyndrome | 58 | 67 | preserve | 77-90 | 77-90 | T7 | atherogenesis | PathologicFunction | 77 | 90 | A6 | A possible role of infection in atherogenesis and acute coronary syndromes. | 39-120 | 39 | 120 | A possible @PREDICAT$ of @SUBJECT$ in @OBJECT$ and acute coronary syndromes. |
Uncommitted | preserve | 12-15 | 12-15 | T3 | for | TREATS | 12 | 15 | preserve | 0-11 | 0-11 | T1 | Antibiotics | Antibiotic | 0 | 11 | preserve | 16-37 | 27-37 | T2 | myocardial infarction | DiseaseOrSyndrome | 16 | 37 | A7 | Antibiotics for myocardial infarction? | 0-38 | 0 | 38 | @SUBJECT$ @PREDICAT$ @OBJECT$ ? |
Possible | preserve | 50-54 | 50-54 | T9 | role | AFFECTS | 50 | 54 | preserve | 58-67 | 58-67 | T6 | infection | DiseaseOrSyndrome | 58 | 67 | preserve | 95-119 | 110-119 | T8 | acute coronary syndromes | DiseaseOrSyndrome | 95 | 119 | A8 | A possible role of infection in atherogenesis and acute coronary syndromes. | 39-120 | 39 | 120 | A possible @PREDICAT$ of @SUBJECT$ in atherogenesis and @OBJECT$ . |
Fact | preserve | 2066-2073 | 2066-2073 | T107 | therapy | TREATS | 2,066 | 2,073 | preserve | 2052-2065 | 2052-2065 | T102 | antibacterial | Antibiotic | 2,052 | 2,065 | preserve | 2078-2101 | 2094-2101 | T104 | coronary artery disease | DiseaseOrSyndrome | 2,078 | 2,101 | A9 | Future large-scale clinical trials are needed to further evaluate the evidence of causality and the efficacy of antibacterial therapy for coronary artery disease. | 1926-2102 | 1,926 | 2,102 | Future large-scale clinical trials are needed to further evaluate the evidence of causality and the efficacy of @SUBJECT$ @PREDICAT$ for @OBJECT$ . |
Fact | preserve | 561-589 | 584-589 | T39 | vascular smooth muscle cells | PART_OF | 561 | 589 | preserve | 570-589 | 584-589 | T35 | smooth muscle cells | Cell | 570 | 589 | preserve | 561-569 | 561-569 | T34 | vascular | BodyPartOrganOrOrganComponent | 561 | 569 | A10 | Infectious organisms may influence the atherosclerotic process through direct local effects on the coronary endothelium, on vascular smooth muscle cells and on macrophages in the atherosclerotic lesion. | 424-645 | 424 | 645 | Infectious organisms may influence the atherosclerotic process through direct local effects on the coronary endothelium, on @OBJECT$ @PREDICAT$ @SUBJECT$ and on macrophages in the atherosclerotic lesion. |
Fact | preserve | 894-897 | 894-897 | T59 | had | PROCESS_OF | 894 | 897 | preserve | 898-909 | 902-909 | T58 | hot flashes | SignOrSymptom | 898 | 909 | preserve | 879-887 | 879-887 | T57 | patients | PatientOrDisabledGroup | 879 | 887 | A1 | Fourteen patients (66%) had hot flashes. | 870-910 | 870 | 910 | Fourteen @OBJECT$ (66%) @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 431-433 | 431-433 | T37 | in | PROCESS_OF | 431 | 433 | preserve | 420-430 | 420-430 | T30 | depression | Finding | 420 | 430 | preserve | 443-451 | 443-451 | T31 | patients | PatientOrDisabledGroup | 443 | 451 | A2 | This pilot study describes the course of menopausal symptoms and the incidence of depression in 21 patients who were likely to become acutely estrogen deficient during treatment for breast cancer. | 331-546 | 331 | 546 | This pilot study describes the course of menopausal symptoms and the incidence of @SUBJECT$ @PREDICAT$ 21 @OBJECT$ who were likely to become acutely estrogen deficient during treatment for breast cancer. |
Fact | preserve | 716-725 | 716-725 | T52 | developed | PROCESS_OF | 716 | 725 | preserve | 726-751 | 743-751 | T47 | major depressive disorder | MentalOrBehavioralDysfunction | 726 | 751 | preserve | 701-709 | 701-709 | T46 | patients | PatientOrDisabledGroup | 701 | 709 | A4 | Eight patients (38%) developed major depressive disorder, the majority within 6 months of starting treatment. | 695-810 | 695 | 810 | Eight @OBJECT$ (38%) @PREDICAT$ @SUBJECT$ , the majority within 6 months of starting treatment. |
Probable | preserve | 236-240 | 236-240 | T23 | risk | PREDISPOSES | 236 | 240 | preserve | 158-169 | 162-169 | T15 | hot flashes | SignOrSymptom | 158 | 169 | preserve | 244-275 | 267-275 | T18 | major depressive disorder | MentalOrBehavioralDysfunction | 244 | 275 | A7 | The change of estrogen function, represented by amenorrhea or hot flashes, that results from breast cancer treatment may increase the risk of major depressive disorder in those women undergoing treatment for breast cancer. | 96-330 | 96 | 330 | The change of estrogen function, represented by amenorrhea or @SUBJECT$ , that results from breast cancer treatment may increase the @PREDICAT$ of @OBJECT$ in those women undergoing treatment for breast cancer. |
Fact | preserve | 63-65 | 63-65 | T9 | in | PROCESS_OF | 63 | 65 | preserve | 53-62 | 53-62 | T5 | syndromes | DiseaseOrSyndrome | 53 | 62 | preserve | 86-94 | 86-94 | T7 | patients | PatientOrDisabledGroup | 86 | 94 | A8 | Iatrogenic acute estrogen deficiency and psychiatric syndromes in breast cancer patients. | 0-95 | 0 | 95 | Iatrogenic acute estrogen deficiency and psychiatric @SUBJECT$ @PREDICAT$ breast cancer @OBJECT$ . |
Fact | preserve | 833-836 | 833-836 | T56 | had | PROCESS_OF | 833 | 836 | preserve | 837-846 | 837-846 | T54 | dysphoria | MentalOrBehavioralDysfunction | 837 | 846 | preserve | 818-826 | 818-826 | T53 | patients | PatientOrDisabledGroup | 818 | 826 | A9 | Twenty patients (95%) had dysphoria and/or insomnia. | 811-869 | 811 | 869 | Twenty @OBJECT$ (95%) @PREDICAT$ @SUBJECT$ and/or insomnia. |
Fact | preserve | 66-94 | 86-94 | T8 | breast cancer patients | PROCESS_OF | 66 | 94 | preserve | 66-79 | 73-79 | T6 | breast cancer | NeoplasticProcess | 66 | 79 | preserve | 86-94 | 86-94 | T7 | patients | PatientOrDisabledGroup | 86 | 94 | A10 | Iatrogenic acute estrogen deficiency and psychiatric syndromes in breast cancer patients. | 0-95 | 0 | 95 | Iatrogenic acute estrogen deficiency and psychiatric syndromes in @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 972-994 | 986-994 | T68 | breast cancer patients | PROCESS_OF | 972 | 994 | preserve | 972-985 | 979-985 | T62 | breast cancer | NeoplasticProcess | 972 | 985 | preserve | 986-994 | 986-994 | T63 | patients | PatientOrDisabledGroup | 986 | 994 | A11 | While this is only pilot data, these data suggest that breast cancer patients whose treatment precipitates menopausal symptoms should be targeted for diagnosis of depression and treated if diagnosed. | 911-1128 | 911 | 1,128 | While this is only pilot data, these data suggest that @SUBJECT$ @PREDICAT$ @OBJECT$ whose treatment precipitates menopausal symptoms should be targeted for diagnosis of depression and treated if diagnosed. |
Fact | preserve | 63-65 | 63-65 | T9 | in | PROCESS_OF | 63 | 65 | preserve | 17-36 | 26-36 | T3 | estrogen deficiency | DiseaseOrSyndrome | 17 | 36 | preserve | 86-94 | 86-94 | T7 | patients | PatientOrDisabledGroup | 86 | 94 | A12 | Iatrogenic acute estrogen deficiency and psychiatric syndromes in breast cancer patients. | 0-95 | 0 | 95 | Iatrogenic acute @SUBJECT$ and psychiatric syndromes @PREDICAT$ breast cancer @OBJECT$ . |
Probable | preserve | 236-240 | 236-240 | T23 | risk | PREDISPOSES | 236 | 240 | preserve | 144-154 | 144-154 | T14 | amenorrhea | DiseaseOrSyndrome | 144 | 154 | preserve | 244-275 | 267-275 | T18 | major depressive disorder | MentalOrBehavioralDysfunction | 244 | 275 | A14 | The change of estrogen function, represented by amenorrhea or hot flashes, that results from breast cancer treatment may increase the risk of major depressive disorder in those women undergoing treatment for breast cancer. | 96-330 | 96 | 330 | The change of estrogen function, represented by @SUBJECT$ or hot flashes, that results from breast cancer treatment may increase the @PREDICAT$ of @OBJECT$ in those women undergoing treatment for breast cancer. |
Fact | preserve | 1330-1358 | 1353-1358 | T68 | vascular smooth muscle cells | PART_OF | 1,330 | 1,358 | preserve | 1339-1358 | 1353-1358 | T67 | smooth muscle cells | Cell | 1,339 | 1,358 | preserve | 1330-1338 | 1330-1338 | T66 | vascular | BodyPartOrganOrOrganComponent | 1,330 | 1,338 | A2 | This increased reactivity to pressor factors may be due to an inadequate nitric oxide generation by vascular endothelium and to increased sodium and calcium concentration in vascular smooth muscle cells. | 1144-1359 | 1,144 | 1,359 | This increased reactivity to pressor factors may be due to an inadequate nitric oxide generation by vascular endothelium and to increased sodium and calcium concentration in @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 1327-1329 | 1327-1329 | T69 | in | LOCATION_OF | 1,327 | 1,329 | preserve | 1339-1358 | 1353-1358 | T67 | smooth muscle cells | Cell | 1,339 | 1,358 | preserve | 1305-1312 | 1305-1312 | T65 | calcium | BiologicallyActiveSubstance | 1,305 | 1,312 | A3 | This increased reactivity to pressor factors may be due to an inadequate nitric oxide generation by vascular endothelium and to increased sodium and calcium concentration in vascular smooth muscle cells. | 1144-1359 | 1,144 | 1,359 | This increased reactivity to pressor factors may be due to an inadequate nitric oxide generation by vascular endothelium and to increased sodium and @OBJECT$ concentration @PREDICAT$ vascular @SUBJECT$ . |
Fact | preserve | 1832-1841 | 1832-1841 | T97 | treatment | TREATS | 1,832 | 1,841 | preserve | 1727-1749 | 1745-1749 | T91 | sodium-restricted diet | TherapeuticOrPreventiveProcedure | 1,727 | 1,749 | preserve | 1866-1878 | 1866-1878 | T96 | hypertension | DiseaseOrSyndrome | 1,866 | 1,878 | A4 | As to the therapeutic approach, the low-energy sodium-restricted diet associated with increased physical activity, represents the cornerstones of treatment for the obesity-related hypertension. | 1674-1879 | 1,674 | 1,879 | As to the therapeutic approach, the low-energy @SUBJECT$ associated with increased physical activity, represents the cornerstones of @PREDICAT$ for the obesity-related @OBJECT$ . |
Fact | preserve | 2092-2106 | 2098-2106 | T108 | obese patients | PROCESS_OF | 2,092 | 2,106 | preserve | 2092-2097 | 2092-2097 | T106 | obese | DiseaseOrSyndrome | 2,092 | 2,097 | preserve | 2098-2106 | 2098-2106 | T107 | patients | PatientOrDisabledGroup | 2,098 | 2,106 | A9 | If this approach fails, the pharmacological treatment becomes necessary, and the use of the converting enzyme inhibitors seems to be the most appropriate choice of drug therapy for hypertensive obese patients. | 1880-2107 | 1,880 | 2,107 | If this approach fails, the pharmacological treatment becomes necessary, and the use of the converting enzyme inhibitors seems to be the most appropriate choice of drug therapy for hypertensive @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 129-153 | 146-153 | T13 | overweight persons | PROCESS_OF | 129 | 153 | preserve | 129-139 | 129-139 | T6 | overweight | SignOrSymptom | 129 | 139 | preserve | 146-153 | 146-153 | T7 | persons | PopulationGroup | 146 | 153 | A10 | While the prevalence of hypertension is clearly increased among the overweight persons, the pathophysiological mechanisms underlying this frequent association of obesity and hypertension are still poorly understood. | 61-288 | 61 | 288 | While the prevalence of hypertension is clearly increased among the @SUBJECT$ @PREDICAT$ @OBJECT$ , the pathophysiological mechanisms underlying this frequent association of obesity and hypertension are still poorly understood. |
Fact | preserve | 1327-1329 | 1327-1329 | T69 | in | LOCATION_OF | 1,327 | 1,329 | preserve | 1339-1358 | 1353-1358 | T67 | smooth muscle cells | Cell | 1,339 | 1,358 | preserve | 1294-1300 | 1294-1300 | T64 | sodium | BiologicallyActiveSubstance | 1,294 | 1,300 | A13 | This increased reactivity to pressor factors may be due to an inadequate nitric oxide generation by vascular endothelium and to increased sodium and calcium concentration in vascular smooth muscle cells. | 1144-1359 | 1,144 | 1,359 | This increased reactivity to pressor factors may be due to an inadequate nitric oxide generation by vascular endothelium and to increased @OBJECT$ and calcium concentration @PREDICAT$ vascular @SUBJECT$ . |
Fact | preserve | 851-896 | 887-896 | T68 | celecoxib, a highly selective COX-2 inhibitor | higher_than | 851 | 896 | preserve | 851-860 | 851-860 | T45 | celecoxib | OrganicChemical | 851 | 860 | preserve | 919-926 | 919-926 | T48 | placebo | MedicalDevice | 919 | 926 | A1 | Preliminary data suggest that celecoxib, a highly selective COX-2 inhibitor, is superior to placebo and similar to traditional NSAIDs in the short-term treatment of pain due to osteoarthritis, although it has been associated with adverse effects such as headache, change in bowel habits, abdominal discomfort, and dizziness. | 814-1163 | 814 | 1,163 | Preliminary data suggest that @SUBJECT$ @PREDICAT$ , is superior to @OBJECT$ and similar to traditional NSAIDs in the short-term treatment of pain due to osteoarthritis, although it has been associated with adverse effects such as headache, change in bowel habits, abdominal discomfort, and dizziness. |
Fact | preserve | 1600-1602 | 1600-1602 | T104 | as | same_as | 1,600 | 1,602 | preserve | 1550-1559 | 1550-1559 | T93 | rofecoxib | OrganicChemical | 1,550 | 1,559 | preserve | 1615-1621 | 1615-1621 | T95 | NSAIDs | PharmacologicSubstance | 1,615 | 1,621 | A2 | In the treatment of osteoarthritis, rofecoxib has been shown to be as effective as traditional NSAIDs and may cause fewer endoscopically documented ulcers, but its complete adverse-effect profile is not known. | 1514-1735 | 1,514 | 1,735 | In the treatment of osteoarthritis, @SUBJECT$ has been shown to be as effective @PREDICAT$ traditional @OBJECT$ and may cause fewer endoscopically documented ulcers, but its complete adverse-effect profile is not known. |
Fact | preserve | 997-1009 | 997-1000 | T66 | due to | CAUSES | 997 | 1,009 | preserve | 1010-1024 | 1010-1024 | T54 | osteoarthritis | DiseaseOrSyndrome | 1,010 | 1,024 | preserve | 992-996 | 992-996 | T53 | pain | SignOrSymptom | 992 | 996 | A3 | Preliminary data suggest that celecoxib, a highly selective COX-2 inhibitor, is superior to placebo and similar to traditional NSAIDs in the short-term treatment of pain due to osteoarthritis, although it has been associated with adverse effects such as headache, change in bowel habits, abdominal discomfort, and dizziness. | 814-1163 | 814 | 1,163 | Preliminary data suggest that celecoxib, a highly selective COX-2 inhibitor, is superior to placebo and similar to traditional NSAIDs in the short-term treatment of @OBJECT$ @PREDICAT$ @SUBJECT$ , although it has been associated with adverse effects such as headache, change in bowel habits, abdominal discomfort, and dizziness. |
Fact | preserve | 1600-1602 | 1600-1602 | T103 | as | compared_with | 1,600 | 1,602 | preserve | 1550-1559 | 1550-1559 | T93 | rofecoxib | OrganicChemical | 1,550 | 1,559 | preserve | 1615-1621 | 1615-1621 | T95 | NSAIDs | PharmacologicSubstance | 1,615 | 1,621 | A4 | In the treatment of osteoarthritis, rofecoxib has been shown to be as effective as traditional NSAIDs and may cause fewer endoscopically documented ulcers, but its complete adverse-effect profile is not known. | 1514-1735 | 1,514 | 1,735 | In the treatment of osteoarthritis, @SUBJECT$ has been shown to be as effective @PREDICAT$ traditional @OBJECT$ and may cause fewer endoscopically documented ulcers, but its complete adverse-effect profile is not known. |
Probable | preserve | 771-776 | 771-776 | T42 | cause | CAUSES | 771 | 776 | preserve | 629-634 | 629-634 | T30 | NSAID | PharmacologicSubstance | 629 | 634 | preserve | 800-812 | 805-812 | T38 | side effects | PathologicFunction | 800 | 812 | A5 | Theoretically, an NSAID that inhibits COX-2 selectively should decrease inflammation but not influence normal physiologic functions and thus should cause fewer gastrointestinal side effects. | 611-813 | 611 | 813 | Theoretically, an @SUBJECT$ that inhibits COX-2 selectively should decrease inflammation but not influence normal physiologic functions and thus should @PREDICAT$ fewer gastrointestinal @OBJECT$ . |
Fact | preserve | 1521-1530 | 1521-1530 | T105 | treatment | TREATS | 1,521 | 1,530 | preserve | 1615-1621 | 1615-1621 | T95 | NSAIDs | PharmacologicSubstance | 1,615 | 1,621 | preserve | 1534-1548 | 1534-1548 | T92 | osteoarthritis | DiseaseOrSyndrome | 1,534 | 1,548 | A6 | In the treatment of osteoarthritis, rofecoxib has been shown to be as effective as traditional NSAIDs and may cause fewer endoscopically documented ulcers, but its complete adverse-effect profile is not known. | 1514-1735 | 1,514 | 1,735 | In the @PREDICAT$ of @OBJECT$ , rofecoxib has been shown to be as effective as traditional @SUBJECT$ and may cause fewer endoscopically documented ulcers, but its complete adverse-effect profile is not known. |
Fact | preserve | 1220-1222 | 1220-1222 | T80 | as | same_as | 1,220 | 1,222 | preserve | 1164-1173 | 1164-1173 | T69 | Celecoxib | OrganicChemical | 1,164 | 1,173 | preserve | 1235-1241 | 1235-1241 | T71 | NSAIDs | PharmacologicSubstance | 1,235 | 1,241 | A8 | Celecoxib also has been shown to be as effective as traditional NSAIDs in the treatment of rheumatoid arthritis, but it may cause fewer adverse effects, including endoscopically documented ulcers. | 1164-1380 | 1,164 | 1,380 | @SUBJECT$ also has been shown to be as effective @PREDICAT$ traditional @OBJECT$ in the treatment of rheumatoid arthritis, but it may cause fewer adverse effects, including endoscopically documented ulcers. |
Fact | preserve | 851-896 | 887-896 | T64 | celecoxib, a highly selective COX-2 inhibitor | ISA | 851 | 896 | preserve | 851-860 | 851-860 | T45 | celecoxib | OrganicChemical | 851 | 860 | preserve | 881-896 | 887-896 | T46 | COX-2 inhibitor | OrganicChemical | 881 | 896 | A9 | Preliminary data suggest that celecoxib, a highly selective COX-2 inhibitor, is superior to placebo and similar to traditional NSAIDs in the short-term treatment of pain due to osteoarthritis, although it has been associated with adverse effects such as headache, change in bowel habits, abdominal discomfort, and dizziness. | 814-1163 | 814 | 1,163 | Preliminary data suggest that @SUBJECT$ @PREDICAT$ @OBJECT$ , is superior to placebo and similar to traditional NSAIDs in the short-term treatment of pain due to osteoarthritis, although it has been associated with adverse effects such as headache, change in bowel habits, abdominal discomfort, and dizziness. |